Purpose: The aim of this study was to develop a model that optimizes the fiducial marker locations in the prostate to increase detectability of the markers in the projected EPID images during VMAT treatments.
alignment of prostate using portal imaging. In most of the recently developed techniques, fiducial markers were used as a prostate margin tracker either by MV, kV or kV-MV combined images. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] It is important to note that the use of kV imaging techniques is not available in all clinics, and the additional dose that would be applied for every treatment fraction is of concern as well. Specialized equipment such as Calypso system (Calypso Medical Technologies, Inc., Seattle, WA, USA) was also used, but not as widely as radiopaque fiducial markers.
With the help of the MV imager, real-time target localization can be achieved by tracking the implanted fiducial markers without added dose to the patient. However, there are two major fundamental challenges with MV-based fiducial marker tracking techniques for VMAT deliveries: (a) frequently blocked radiation fields by the multileaf collimator (MLC) and (b) potential large time intervals between two detections. 8 There should be some optimum way to maximize the possibility of being detected as a real-time target tracker, as well as serve its original purpose of being a prostate surrogate.
Thus, in this study, we aim to develop a model based on several simulated fiducial marker locations in the prostate to identify the optimal marker locations for MV EPID-based tracking during VMAT treatments. In addition, we propose a detectability score to predict the detectability for MV-based fiducial marker tracking techniques and recommend locations within the prostate to implant the fiducial markers to increase detectability of the prostate during treatments.
| MATERIALS AND METHODS
The first part of the study focused on developing a model based on several simulated fiducial marker locations. The origin of imaginary fiducial marker locations was positioned in the center of patient prostate, which was at the center of the MLC field. DICOM RT plan files from previously treated patients were used to generate the detectability score as described in the following sections.
2.A | Fiducial marker locations
The radiopaque fiducial marker used in our institution, having a size of 0.8 9 0.8 9 5 mm 3 , was modeled as a 2 9 2 9 6 mm 3 cuboid volume due to the scatter on the CT images. Typically, in our institute, four fiducial markers are inserted into the patient via an ultrasound-guided needle and a grid template (CIVCO Medical Solutions, Coralville, IA, USA), a tool for pinpointing the prostate location in transverse plane to accurately deposit the marker into the desig- Table 1 .
To elaborate on the assignment of each group, the location identification for each fiducial marker, and their locations were given as a pattern group letter, followed by parameter "a" value (X-Y plane separation) and a subgroup number after the dashed line at the T A B L E 1 List of all the locations for the 40 fiducial marker patterns and their corresponding groups/IDs (unit in mm for parameter "a" and "z"). 
2.B | Prostate plans
Total of 101 previously treated prostate VMAT cases, containing 202 arcs were used in this study. All plans were created using Varian
Eclipse treatment planning system (Varian Medical Systems, Inc., Palo Alto, CA, USA). The plans were chosen such that the target was limited to the prostate with corresponding PTV margin only.
2.C | Overlapping ratio
The projected fiducial marker locations that overlap at a particular EPID projection will reduce the detectability of the prostate at that EPID projection angle, therefore, the overlap ratio was introduced to take into account the reduction of prostate detectability due to overlap of projected fiducial marker locations on the EPID images.
The overlapping ratio was defined as the ratio of number of control points having overlap of projected fiducial markers on EPID images to the total control points in an arc.
2.D | Detectability score calculation
A particular fiducial marker is considered to be detectable if the area comprising a 3 mm radius around the corresponding fiducial marker center was unblocked by the MLC or the jaws. The unblocked area ðA ij u Þ is calculated for each fiducial marker i at control point j. The detectability score was calculated as the percentage of the summed unblocked area over the total area (A) for all fiducial markers at control points j.
The detectability of the prostate location on an EPID image is greatly affected by the number of fiducial markers detected on that image. A detection-number weighting factor (w d ) was introduced to F I G . 1. Fiducial marker location demonstration. Each subplot shown the examples of the corresponding pattern group, in which subgroup I was plotted in black color, subgroup II: gray, subgroup III: blue and subgroup IV: red. Different X-Y plane separations ("a" value) were demonstrated in various transparencies. In subplot D, partial length indicated that the markers were partially overlapped with the adjacent ones.
penalize the control points that had less than three unblocked fiducial markers detected (a valid fiducial marker detection has an area larger than 3/4 of its original area unblocked, which is 3/16 of A).
The w d weighting factor was set to 1 if three or more markers were visible on a projected EPID image for a particular control point. The factor is set to 2/3 for only two marker detections, 1/3 for only one marker detection, and zero if no markers were detected.
In addition, an overlap weighting factor (w o ) was incorporated into the detectability score to take into account the overlapped markers on the projected EPID images. This factor is different from the aforementioned overlapping ratio in two aspects: (a) it was applied only for the unblocked markers while the overlapping ratio was calculated for the open field, and (b) for each control point, the total number of overlapped markers are counted and treated differently. The w o weighting factor was set to 1 if there is no overlap between all four fiducial markers, w o was set to 0.5 when two markers overlap, and 1/3 for all other cases.
The fiducial markers that were blocked by the MLC or jaws for consecutive control points were additionally penalized in the detectability score with a weighting factor (w ts ). w ts was given for the entire arc. Each segment of consecutive control points that had no detection was first counted. The threshold of 15 control points was given to sift out the segments that were not deemed as large time interval. One minus the half of summed control points of all remaining segments over the total number of control points was the final w ts value.
Thus, the detectability score (D) was calculated as:
where i is the fiducial marker number, j is control point number, n corresponds to the total number of control points for that arc, w d is the weighting factor of detectable number of markers, w o is the overlapping weighting factor, w ts is the time span weighing factor, A ij u is the unblocked area for i th fiducial marker at control point j, and A is the total area of the four fiducial markers.
2.E | Optimal distance analysis
The detectability score was determined for the 40 fiducial marker implant patterns illustrated in Table 1 and Fig. 1 . An optimal distance from the center of the prostate to implant the fiducial markers was determined based on the detectability score results. The markers were assumed to be distributed as a circular pattern in X-Y plane.
The shortest radius to the center was assumed to be the separation distance of the X-Y plane. Along the Z direction, the score was evaluated via shortest separation distance between marks; if the markers happened to share the same Z value, they were considered as not separated at all.
2.F | The Modulation Complexity Score
The Modulation Complexity Score (MCS) value was calculated for each arc of all the prostate plans. The calculation method was based on the equation described by McNiven.
14 Analysis was performed between the MCS and the detectability to see the correlation between complexity of the MLC motion and the fiducial marker detection.
| RESULTS
As shown in The overall detectability scores are shown in Fig. 3 . In general, the detectability score decreases as the fiducial markers get more
Results of Overlapping ratio, a general trend line of each group was projected onto the side plane. result in a low detectability score, indicating that complexity of the plan also is a factor in the detectability of the prostate during treatments.
| DISCUSSION
As seen from Fig. 2 , the overlapping ratio decreases as markers are separated in the X-Y plane. The ratio will drop to 0 in the superiorinferior (Z) direction if the separation interval between two marker centers is greater than the length of one fiducial marker; otherwise it will remain constant. These results indicate that the markers should be placed as far away from each other in each direction to avoid overlap in the projected EPID images. In certain clinical environment, one marker is considered sufficient enough to pinpoint the target location at a time. Then, the detection-number weighting factor would be assigned to 1 for cases that at least one valid detection is observed and 0 for no detection.
To take these situations into account, a recalculation of the detectability score with the new detection weighting factor was presented here in Fig. 6 .
The detectability score would tend to favor the ones scattered more on the X-Y plane. This is reasonable. Majorly, the MLC openings are around the central region. The MLC will irradiate occasionally around the peripheral area, which, with no detection number penalty, gives a boost to detectability score in the original scores.
Compared to the original results, the more peripheral the markers get, the higher the chance will be blocked. Therefore, with the original detect number weighting factor, the patterns with more scattered markers got lower values. Whether to choose the original format and simple detection-number weighting format is purely depended on how it is going to be implemented in the clinical environment. However, the final results remain the same.
The relationship between MCS and detectability indicated that lower complexity of the treatment field would improve the overall performance of the marker tracking technique via MV imager. Future work can be done to maintain the same treatment plan quality while decreasing the complexity of the MLC movements. 
| CONCLUSION S
Tracking the movement of the prostate is crucial during treatment to ensure the intended dose is given to the target while 
